LOGIN  |  REGISTER
Amneal Pharmaceuticals
Recursion

Natera to Participate in November Investor Conferences

November 07, 2023 | Last Trade: US$160.12 1.03 -0.64

AUSTIN, Texas / Nov 07, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in November.

 

Stephens Annual Investment Conference

 

 

Tuesday, Nov. 14 at 12:00 pm ET | 9:00 am PT in Nashville, TN

 

Piper Sandler 35th Annual Healthcare Conference

 

 

Tuesday, Nov. 28 at 2:30 pm ET | 11:30 am PT in New York, NY

A live webcast and audio archive of each event may be accessed through the investor relations section of the Natera website at investor.natera.com. Replays of the events will be available shortly following the conferences.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page